Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14081462 | 0.98 | CYP1A2 (0.52) | CYP1A2NCF1ACHEGNAO1GNAI3 | |
| SCHEMBL12038519 | 0.98 | CYP1A2 (0.52) | CYP1A2NCF1ACHEGNAO1GNAI3 | |
| SCHEMBL14081460 | 0.88 | NCF1 (0.50) | CYP1A2NCF1ACHEGNAO1GNAI3 | |
| SCHEMBL8114365 | 0.87 | CYP1A2 (0.50) | CYP1A2NCF1ACHEGNAO1GNAI3 | |
| SCHEMBL8587237 | 0.85 | CYP1A2 (0.50) | CYP1A2HRH3CARM1PRMT6PRMT8 | |
| SCHEMBL10153844 | 0.83 | CYP1A2 (0.54) | CYP1A2HRH3CARM1PRMT6PRMT8 | |
| SCHEMBL10949210 | 0.83 | CHRM5 (0.54) | CYP1A2HRH3CHRM5ADRA2CSIGMAR1 | |
| SCHEMBL22224171 | 0.83 | ACHE (0.50) | CYP1A2NCF1ACHEGNAO1GNAI3 | |
| SCHEMBL24754307 | 0.83 | NCF1 (0.45) | NCF1ACHEGNAO1GNAI3GNAI1 | |
| SCHEMBL22307041 | 0.83 | GNAO1 (0.47) | NCF1ACHEGNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-8957073-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. | 2015-02-17 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7973012-B2 | C-phenyl glycitol compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7956060-B2 | Pyrimidine derivative compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-7956060-B2 | Pyrimidine derivative compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20110130286-A1 | Piperazine Compounds with Herbicidal Effect | BASF SE (DE) | 2011-06-02 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090012060-A1 | Antitumor Agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012060-A1 | Antitumor Agent | NR1H3, NR1I3, NR0B1 | CYP1A2 1987/4885NCF1 1155/4885ACHE 4782/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | CYP1A2 749/4885NCF1 3772/4885ACHE 2562/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | CYP1A2 1017/4885NCF1 586/4885ACHE 568/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | CYP1A2 4784/4885NCF1 484/4885ACHE 3506/4885 |
| US-20110130286-A1 | Piperazine Compounds with Herbicidal Effect | CAT, DDT, CIP2A | CYP1A2 31/4885NCF1 3314/4885ACHE 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.